Lupin Formoflo-G is a first-of-its-kind MDI that combines Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate for the long-term management and treatment of moderate to severe COPD
The Differin Gel, 0.1% (OTC) market achieved annual sales of approximately $45.8 million
NICE’s recommendation is supported by positive results from the Phase 3 Balance study
Regeneron will receive $1 billion upfront from Sanofi, with up to $7 billion more available through development, regulatory and commercial milestones
Abbott said SimpleScreen CRC is designed primarily for eligible patients who decline or do not complete preferred stool-based or visual screening options
The rebrand is aimed at reflecting SPI Pharma’s evolution and its focus on helping customers tackle increasingly complex formulation challenges
Ayush services sector with its economic contribution estimated at US $36.92 billion in FY 2024-25
Multi-year investment reinforces U.S. business expansion and adds to $7 billion in U.S. pharma R&D and manufacturing expenditure over past five years
Apitoria Pharma Private Limited now owns 80% of A1 Biochem Labs (India) Private Limited
The transaction outlines a subscription where Zydus Lifesciences will purchase 50% of the total paid-up equity share capital of the joint venture
FICCI's Bharat Life Sciences Award held in New Delhi recognises Dr. Jain's leadership in building a collaborative biopharma ecosystem through Mumbai Biocluster
The partnership will bring together Apollo’s clinical ecosystem with BITS Pilani’s expertise in engineering, technology and data science to tackle healthcare challenges through research, education and industry-focused training
Retatrutide is an investigational, first-in-class combination of GIP, GLP-1 and glucagon receptor activity
Novel, non-steroidal topical PDE4 inhibitor is approved for adults and pediatric patients aged 2 years and older
The deal includes a $300 million upfront payment, with the remaining value tied to development, regulatory and commercial milestones
Biodeal also plans to add pre-filled syringe (PFS) and lyophilised formats
AstraZeneca will take a roughly 12% stake in Summit Therapeutics under a deal aimed at accelerating development of ivonescimab
The acquisition provides access to Bliss GVS Pharma’s established portfolio of branded formulations, manufacturing infrastructure and presence across multiple therapeutic segments
Subscribe To Our Newsletter & Stay Updated
